Skip to content

Author

Qingyun Wu

We have 2 of 56 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Calsyntenin-2 promotes the pathology of acute myeloid leukemia via activation of the JAK2-STAT3 signaling pathway.

PURPOSE Although considerable progress has been made in the treatment of acute myeloid leukemia (AML), therapeutic outcomes remain unsatisfactory. Thus, it is of great important to investigate the leukemiagenesis mechanism of AML. Previous studies indicated that Calsyntenin-2 (CLSTN2) was closely associated with the pr...

Yu-Ting Dou, Xu Cao, Ke Ji et al. · 0 citations
Jul 2026

Long-term follow-up of third generation anti-CD30 CAR T-cell therapy in relapsed/refractory CD30+ lymphomas: a single-arm, multicentre, phase 1-2 trial.

Third-generation anti-CD30 CAR T-cell therapy demonstrates high efficacy and a favorable safety profile in r/r CD30+ lymphoma patients and addition of auto-HSCT following CAR T-cell therapy improves depth of remission and potentially enhances OS and PFS.

Xiang-Min Wang, Qing Zhang, Dong-Mei Yan et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.